Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were initially developed as glucose-lowering agents in patients with type-2 diabetes. However, available data from clinical trials and meta-analyses suggest that SGLT2i have pleiotropic benefits in reducing mortality and delaying the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Junhao, Guo, Luying, Wang, Rending, Chen, Jianghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601939/
https://www.ncbi.nlm.nih.gov/pubmed/37901712
http://dx.doi.org/10.1159/000530395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601939/
https://www.ncbi.nlm.nih.gov/pubmed/37901712
http://dx.doi.org/10.1159/000530395

Ejemplares similares